This study is looking at how breast cancer tumors change when treated with endocrine therapy before surgery. Researchers are giving patients with hormone receptor-positive (HR+), HER2-negative breast cancer either aromatase inhibitors or tamoxifen for 4-12 weeks before their surgery. The goal is to see how these treatments affect certain proteins in the tumor, specifically HER-1, HER-2, and HER-3 receptor tyrosine kinases. By comparing these protein levels before and after treatment, the study hopes to find ways to predict which patients will respond best to endocrine therapy and identify new treatment targets. You may be able to join if you are a woman aged 18 or older with stage I or II breast cancer that is clinically lymph node negative. The study plans to enroll 100 participants, but its current status is unclear.

Study design

This is an interventional study that will enroll 100 participants. It is an exploratory phase II study where all participants receive standard-of-care anti-estrogen treatment.

What's involved

You would receive either aromatase inhibitors or tamoxifen for 4-12 weeks before your surgery. Tumor samples will be taken at the time of surgery to measure protein changes.

Compensation

Not stated in the trial record.

Follow-up

Changes in protein expression are measured at the time of surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.